AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1460163 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT, fluoxetine, or amitriptyline
Number of subjects: 21
Study 1460163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined studies
Number of subjects: 21
Study 6229740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g metronidazole suppository, administered 12-hourly starting 48 hours before elective surgery
Number of subjects: 10
Study 6229740 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g metronidazole i.v. over 20 minutes and 1 g suppository at premedication, continued with one suppository 12-hourly
Number of subjects: 10
Study 6229740 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g metronidazole suppository, administered 8-hourly starting 24 hours before surgery for high-risk patients
Number of subjects: 10
Study 6229740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal treatment
Number of subjects: 10
Study 30676094 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mM NAC
Number of subjects: 13
Study 30676094 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mM NAC
Number of subjects: 13
Study 30676094 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mM NAC
Number of subjects: 13
Study 30676094 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mM NAC
Number of subjects: 13
Study 30676094 — intervention group
Group type: COMPARATOR
Intervention: 0 mM NAC
Number of subjects: 13
Study 29579671 — intervention group
Group type: EXPERIMENTAL
Intervention: TRS2˚P risk score
Number of subjects: 9618
Study 30650291 — intervention group
Group type: COMPARATOR
Intervention: Longbishu Capsule (LBS) placebos combined Doxazosin Mesylate Tablet (DMT)
Number of subjects: 360
Study 30650291 — intervention group
Group type: EXPERIMENTAL
Intervention: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT)
Number of subjects: 360
Study 30650291 — intervention group
Group type: COMPARATOR
Intervention: Longbishu Capsule (LBS) combined Doxazosin Mesylate Tablet (DMT) placebos
Number of subjects: 360
Study 24746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture (BVA)
Number of subjects: 60
Study 24746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 60
Study 24746224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (BVA + NSAIDs)
Number of subjects: 60
Study 24746224 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 23172029 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mM fluconazole
Number of subjects: 8
Study 23172029 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine cream
Number of subjects: 8
Study 23172029 — intervention group
Group type: EXPERIMENTAL
Intervention: fluconazole + lidocaine
Number of subjects: 8
Study 23172029 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM N(G)‐monomethyl‐l‐arginine (l‐NMMA)
Number of subjects: 8
Study 23172029 — intervention group
Group type: EXPERIMENTAL
Intervention: fluconazole + l‐NMMA
Number of subjects: 8
Study 23172029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20833973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 16 weeks
Number of subjects: 319
Study 20833973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 319
Study 18166301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 spermicides
Number of subjects: 151
Study 18166301 — intervention group
Group type: COMPARATOR
Intervention: Condom use
Number of subjects: 151
Study 15878759 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated chemotherapy (CT) regimen: 3 cycles of cisplatin and 5-fluorouracil (days 1, 14, and 28) followed by hyperfractionated radiation therapy (RT) (7440 cGy/62 fractions)
Number of subjects: 68
Study 12560354 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg folic acid supplement plus natural diet
Number of subjects: 126
Study 12560354 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary folate to 400 microg/day
Number of subjects: 126
Study 12560354 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus natural diet
Number of subjects: 126
Study 10622750 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 25% albumin
Number of subjects: 28
Study 10622750 — intervention group
Group type: COMPARATOR
Intervention: Normal saline to increase Pra by 2 mm Hg (n = 15)
Number of subjects: 28
Study 10622750 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory variation in Pra
Number of subjects: 28
Study 7791169 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 150 mg/day (Group A)
Number of subjects: 45
Study 7791169 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B)
Number of subjects: 45
Study 2289220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol 40 micrograms/kg twice daily
Number of subjects: 40
Study 2289220 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 100 micrograms/kg three times daily
Number of subjects: 40
Study 7235865 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (B group)
Number of subjects: 60
Study 7235865 — intervention group
Group type: COMPARATOR
Intervention: No follow-up treatment (A group)
Number of subjects: 60
Study 31255504 — intervention group
Group type: COMPARATOR
Intervention: Haemonetics MCS+
Number of subjects: 69
Study 31255504 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo Spectra Optia
Number of subjects: 69
Study 28051319 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (12 weeks, twice a week for 60 minutes, including breathing exercises, yoga pose practice, and supine meditation/relaxation)
Number of subjects: 26
Study 28051319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga practice, maintain usual physical activity)
Number of subjects: 26
Study 26301241 — intervention group
Group type: EXPERIMENTAL
Intervention: Signature CT-based implant positioning system
Number of subjects: 112
Study 26301241 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 112
Study 24565021 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS monitored weaning
Number of subjects: 380
Study 24565021 — intervention group
Group type: COMPARATOR
Intervention: Traditional weaning method
Number of subjects: 380
Study 21372621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Well-Being Therapy (WBT)
Number of subjects: 62
Study 21372621 — intervention group
Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 62
Study 18463106 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein alone
Number of subjects: 6
Study 18463106 — intervention group
Group type: COMPARATOR
Intervention: Meal containing soy protein
Number of subjects: 6
Study 18463106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17133051 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (n = 19)
Number of subjects: 47
Study 17133051 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 21)
Number of subjects: 47
Study 17133051 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (n = 26)
Number of subjects: 47
Study 15849961 — intervention group
Group type: EXPERIMENTAL
Intervention: vax-TyVi
Number of subjects: 323
Study 15849961 — intervention group
Group type: EXPERIMENTAL
Intervention: TYPHIM Vi
Number of subjects: 323
Study 15849961 — intervention group
Group type: COMPARATOR
Intervention: vax-TET
Number of subjects: 323
Study 10972631 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate simvastatin treatment (40 mg/d)
Number of subjects: 151
Study 10972631 — intervention group
Group type: COMPARATOR
Intervention: Deferred simvastatin treatment (40 mg/d after 3 months if LDL-C >3.0 mmol/L)
Number of subjects: 151
Study 10972631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immediate and deferred simvastatin treatment)
Number of subjects: 151
Study 1574970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of naloxone 1 microgram kg‐1 h‐1
Number of subjects: 27
Study 1574970 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 27
Study 4019017 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (30 min of daily self‐selected aerobic activity)
Number of subjects: 78
Study 4019017 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (prescribed exercise training performed every other day)
Number of subjects: 78
Study 4019017 — intervention group
Group type: COMPARATOR
Intervention: Group C (Control, no exercise program)
Number of subjects: 78
Study 31320980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AOC) - 1,000 mg vitamin C, 600 IU vitamin E, and 600 mg α-lipoic acid
Number of subjects: 18
Study 31320980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31320980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AOC)
Number of subjects: 18
Study 29365309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-Pibrentasvir for 8 weeks
Number of subjects: 1208
Study 29365309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-Pibrentasvir for 12 weeks
Number of subjects: 1208
Study 29365309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-Pibrentasvir for 12 weeks (Genotype 3)
Number of subjects: 1208
Study 29365309 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-Daclatasvir for 12 weeks (Genotype 3)
Number of subjects: 1208
Study 29365309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir-Pibrentasvir for 8 weeks (Genotype 3)
Number of subjects: 1208
Study 26352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (3 μg/kg/min)
Number of subjects: 60
Study 26352063 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose dopamine (5 μg/kg/min)
Number of subjects: 60
Study 26352063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dopamine treatment)
Number of subjects: 60
Study 25799714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifecta valve (n = 20)
Number of subjects: 40
Study 25799714 — intervention group
Group type: COMPARATOR
Intervention: Freestyle valve (n = 20)
Number of subjects: 40
Study 22647932 — intervention group
Group type: EXPERIMENTAL
Intervention: Blurring lenses ranging from -0.50 to +1.50 D in 0.25 D steps
Number of subjects: 10
Study 22647932 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-100 numeric rating scale (NRS)
Number of subjects: 10
Study 22647932 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mm visual analog scale (VAS)
Number of subjects: 10
Study 22647932 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 point categorical rating scale (CRS)
Number of subjects: 10
Study 22647932 — intervention group
Group type: EXPERIMENTAL
Intervention: All scales (NRS, VAS, CRS)
Number of subjects: 10
Study 20920275 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase fruits and vegetables and increase physical activity
Number of subjects: 200
Study 20920275 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease saturated fat and increase physical activity
Number of subjects: 200
Study 20920275 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase fruits and vegetables and decrease saturated fat
Number of subjects: 200
Study 20920275 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease saturated fat and decrease sedentary activity
Number of subjects: 200
Study 18606496 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrostimulation (FES) in group G36 (n=9)
Number of subjects: 27
Study 18606496 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrostimulation (FES) in group G24 (n=9)
Number of subjects: 27
Study 18606496 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 27
Study 16412324 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 60
Study 12131261 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 2 x 4 mg (REB)
Number of subjects: 7
Study 12131261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study 12131261 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (REB)
Number of subjects: 7
Study 10421596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide fumarate 0.25 mg
Number of subjects: 302
Study 10421596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide fumarate 0.5 mg
Number of subjects: 302
Study 10421596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide fumarate 1.0 mg
Number of subjects: 302
Study 10421596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 10421596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (all doses)
Number of subjects: 302
Study 10421596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 302
Study 8678066 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 57
Study 8678066 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment in elderly patients
Number of subjects: 57
Study 8678066 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment in younger patients
Number of subjects: 57
Study 8678066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPO treatment)
Number of subjects: 57
Study 1507095 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-cured polymethylmethacrylate
Number of subjects: 53
Study 1507095 — intervention group
Group type: COMPARATOR
Intervention: Autopolymerized polymethylmethacrylate
Number of subjects: 53
Study 6606554 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 6
Study 6606554 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (four times 0.5 g/d)
Number of subjects: 6
Study 6606554 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 6
Study 31783800 — intervention group
Group type: EXPERIMENTAL
Intervention: NeCR intervention (nurse-led eHealth cardiac rehabilitation)
Number of subjects: 146
Study 31783800 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 29367197 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 202
Study 29367197 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 202
Study 26589368 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (5mg/day)
Number of subjects: 111
Study 26589368 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin (10mg/day)
Number of subjects: 111
Study 24706353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic medication (brimonidine and timolol) instilled 5 minutes before injection
Number of subjects: 141
Study 24706353 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic medication
Number of subjects: 141
Study 24706353 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous reflux presence
Number of subjects: 141
Study 24706353 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (with and without prophylactic medication)
Number of subjects: 141
Study 23964445 — intervention group
Group type: EXPERIMENTAL
Intervention: One gram of powdered ginger per day
Number of subjects: 60
Study 23964445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20595646 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 group (2.5 g/d of n‐3 LCPUFA, with 1.67 g of EPA and 0.83 g of DHA)
Number of subjects: 46
Study 20595646 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 16672187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training
Number of subjects: 22
Study 16672187 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 22
Study 15660732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg (t.i.d., n = 33)
Number of subjects: 47
Study 15660732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 47
Study 15660732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg (t.i.d.)
Number of subjects: 47
Study 15660732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12092887 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft midsole shoes
Number of subjects: 24
Study 12092887 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium midsole shoes
Number of subjects: 24
Study 12092887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard midsole shoes
Number of subjects: 24
Study 12092887 — intervention group
Group type: COMPARATOR
Intervention: Downhill running (irrespective of midsole durometer)
Number of subjects: 24
Study 10549836 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate every 6 hours (Group A)
Number of subjects: 66
Study 10549836 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate every 12 hours (Group B)
Number of subjects: 66
Study 7558223 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human brain natriuretic peptide‐32 (0.25 pmol/kg per minute for the first hour and 0.50 pmol/kg per minute for the second hour)
Number of subjects: 6
Study 7558223 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human brain natriuretic peptide‐32
Number of subjects: 6
Study 1993790 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR (dual chamber universal rate‐responsive)
Number of subjects: 22
Study 1993790 — intervention group
Group type: COMPARATOR
Intervention: VVIR (ventricular demand rate‐responsive)
Number of subjects: 22
Study 1993790 — intervention group
Group type: COMPARATOR
Intervention: VVIR and DDIR modes
Number of subjects: 22
Study 1993790 — intervention group
Group type: COMPARATOR
Intervention: DDDD (dual chamber universal)
Number of subjects: 22
Study 1993790 — intervention group
Group type: COMPARATOR
Intervention: VVIR mode
Number of subjects: 22
Study 1993790 — intervention group
Group type: EXPERIMENTAL
Intervention: DDIR
Number of subjects: 22
Study 1993790 — intervention group
Group type: COMPARATOR
Intervention: VVIR
Number of subjects: 22
Study 1993790 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 22
Study 7045365 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone posture for four hours
Number of subjects: 50
Study 7045365 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees head down tilt for 30 minutes followed by supine posture for 3 1/2 hours
Number of subjects: 50
Study 31522849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-0 group (4000 mg peanut protein through to week 104, then discontinued)
Number of subjects: 120
Study 31522849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-300 group (4000 mg peanut protein through to week 104, then 300 mg daily for 52 weeks)
Number of subjects: 120
Study 31522849 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (oat flour)
Number of subjects: 120
Study 31522849 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 31522849 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-0 group
Number of subjects: 120
Study 28002873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil dilation
Number of subjects: 30
Study 28002873 — intervention group
Group type: COMPARATOR
Intervention: Undilated eye
Number of subjects: 30
Study 25682436 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 1509
Study 25682436 — intervention group
Group type: COMPARATOR
Intervention: No ACEi/ARB
Number of subjects: 1509
Study 24344787 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl solution (TFS) 2.7 mg/kg applied 2-4 hours prior to surgery
Number of subjects: 502
Study 24344787 — intervention group
Group type: COMPARATOR
Intervention: Oxymorphone hydrochloride 0.22 mg/kg administered subcutaneously 2-4 hours prior to surgery and every 6 hours for 90 hours
Number of subjects: 502
Study 23066159 — intervention group
Group type: EXPERIMENTAL
Intervention: FSI within 3 years of menarche
Number of subjects: 504
Study 23066159 — intervention group
Group type: COMPARATOR
Intervention: Postponed FSI beyond 3 years of menarche
Number of subjects: 504
Study 19597964 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Outcome Score (TOS)
Number of subjects: 73
Study 19597964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Symptom Complex Severity (MSCS) score
Number of subjects: 73
Study 17631256 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 30
Study 17631256 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 15688096 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular excisions
Number of subjects: 56
Study 15688096 — intervention group
Group type: COMPARATOR
Intervention: Elliptical excisions
Number of subjects: 56
Study 15688096 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular excisions without complications
Number of subjects: 56
Study 15688096 — intervention group
Group type: COMPARATOR
Intervention: Elliptical excisions without complications
Number of subjects: 56
Study 12407029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of all embryos
Number of subjects: 0
Study 12407029 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cryopreservation of all embryos
Number of subjects: 0
Study 12407029 — intervention group
Group type: COMPARATOR
Intervention: i.v. human albumin administration
Number of subjects: 0
Study 12407029 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 0
Study 9809088 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/N2O at 1 and 1.5 MAC
Number of subjects: 25
Study 9809088 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/N2O at 1 and 1.5 MAC
Number of subjects: 25
Study 7544439 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vector containing normal CFTR cDNA (doses: 1, 10, 100, 1000)
Number of subjects: 12
Study 7544439 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vector (highest dose)
Number of subjects: 12
Study 7544439 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 12
Study 7544439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of adenoviral vector
Number of subjects: 12